Celltrion USA today announced the launch of Yuflyma, a high-concentration and citrate-free formulation of Humira biosimilar, providing an alternative option for patients. Yuflyma is indicated for the treatment of eight conditions, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, plaque psoriasis, and hidradenitis suppurativa.1

First approved by the Food and Drug Administration on May 23, 2023, Yuflyma became commercially available among key distributors across the U.S. on July 2nd. Yuflyma is listed at $6,576.50 per month. Yuflyma is available in two device types — auto-injector and pre-filled syringe options.

More than  of patients treated with Humira in the U.S. rely on a high-concentration and citrate-free formulation.2 Yuflyma is a citrate-free formulation that is highly concentrated at. It also maintains stability at or 30 days to provide longer shelf life than Humira and is administered via a latex-free device.1

“The launch of Yuflyma is a critical milestone not only for Celltrion USA, but for patients, healthcare providers, and payers,” said Tom Nusbickel, Chief Commercial Officer at Celltrion USA. “We are committed to providing a patient-centric approach with a focus on increased access to innovative, high-quality biologics in the United States. Celltrion has a demonstrated track record of commercial, regulatory and manufacturing success globally – including the first monoclonal antibody biosimilar infliximab– and our dedicated immunology commercial team is ready to leverage their experience and market knowledge in the U.S.”

Professor Jonathan Kay of UMass Chan Medical School, said: “The launch of Yuflyma provides patients with one of only a few FDA-approved adalimumab biosimilars that has a high-concentration, citrate-free formulation. This formulation can reduce injection discomfort for patients with chronic conditions like rheumatoid arthritis, thereby improving adherence to treatment.”

To improve patients’ and healthcare providers’ experience using Yuflyma, Celltrion USA is proud to offer Celltrion CONNECT Patient Support Program along with Celltrion CARES Co-pay Assistance Program beginning July 10th. The Patient Support Program for Yuflyma will provide benefits verification, prior authorization assistance, and co-pay assistance. Eligible patients with private/commercial insurance may receive Yuflyma for as little as $0 out of pocket per month. Patients who are uninsured or underinsured may be eligible to receive Yuflyma through the Celltrion CONNECT Patient Assistance Program (PAP). Nurses will be available to answer patient questions and provide training. Visit www.CelltrionConnect.com to learn more.

Celltrion is seeking an interchangeability designation from the U.S. FDA for Yuflyma, tentatively expected Q4 in 2024.

 

Source:celltrionhealthcare.com

Report Abuse